Key Highlights
- Profusa (PFSA) shares jumped over 173% following the announcement of a letter of intent to purchase PanOmics, a next-generation sequencing diagnostics platform, from BioInsights LLC through a $30 million equity transaction.
- The agreement grants exclusive access to the PanOmics platform, establishes a 3% royalty on net revenue payable to BioInsights, and provides a board nomination privilege.
- Profusa restructured its current financing arrangements, introducing new senior secured convertible notes valued at up to $12.2 million to support operational needs.
- The company has partnered with Mayo Clinic to develop its Lumee oxygen platform for pancreatic surgical applications, which management projects could generate $26 million in annual revenue.
- Profusa increased its 2026 revenue projection to $1.5M–$3M, compared to the previous range of $500K–$2M, driven by heightened demand from European distributors.
Profusa (PFSA) experienced a dramatic rally on Monday. The micro-cap biotechnology stock climbed more than 173% after revealing a letter of intent to purchase the PanOmics multi-omics diagnostics platform from BioInsights LLC through an all-equity transaction valued at approximately $30 million.
Profusa, Inc. Common Stock, PFSA
The surge comes with important context. The stock remains down approximately 99.92% over the trailing twelve months, and the company maintains a market capitalization of just $870,000.
The letter of intent was initially executed on March 31, 2026, with subsequent amendments on April 3 and April 4. The transaction would transfer exclusive rights to PanOmics’ intellectual property and diagnostic platform to Profusa, with a focus on next-generation sequencing (NGS) technology for oncology diagnostics.
According to the agreement terms, BioInsights will earn a 3% royalty based on net revenues and gain the authority to nominate one independent board member for stockholder review. BioInsights will also grant access to clinical samples to support platform validation efforts.
The deal requires shareholder approval, successful completion of due diligence, and regulatory clearance before finalization. Profusa has indicated plans to secure an additional $10 million through equity financing to support PanOmics validation activities and equipment procurement.
Strategic Rationale Behind the PanOmics Acquisition
The timing of this acquisition aligns with recent CMS reimbursement developments supporting NGS-based oncology testing, which Profusa believes establishes a viable commercial pathway. The transaction aims to broaden revenue streams while the company’s primary LumeeOxygen product undergoes clinical validation.
CEO Dr. Ben Hwang characterized the transaction as contributing $30 million in stockholder equity to the balance sheet and establishing the company within the precision diagnostics sector. Company management will receive new equity compensation equivalent to 12% of fully diluted shares, creating alignment with the expanded business model.
The transaction structure involves issuing both common stock and non-voting preferred stock, with a seven-year lock-up restriction applied to the majority of BioInsights’ equity position.
Mayo Clinic Partnership and Financial Projections
Independent of the acquisition, Profusa has established a collaboration with Mayo Clinic to utilize its Lumee oxygen platform for monitoring during pancreatic surgeries. Management estimates that over 13,000 pancreatic resections occur annually across the United States, representing a potential $26 million annual revenue opportunity.
Regarding financing activities, Profusa modified its securities purchase agreement on April 2, allowing the company to issue up to $12.2 million in additional senior secured convertible notes. A third-tranche note worth $555,555.55 was issued to Ascent Partners Fund, with a 2027 maturity date, accompanied by a warrant for 1,111,111 common shares priced at $0.50.
The company recently abandoned a planned $15 million public offering, opting instead for a smaller capital raise. Profusa also discontinued its Bitcoin treasury reserve approach, selling all Bitcoin holdings.
Profusa has elevated its full-year 2026 revenue guidance to $1.5 million–$3 million, compared to the earlier projection of $500,000–$2 million, attributing the increase to expanded purchase orders from European distributors for the Lumee system.
